Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Progyny ( (PGNY) ) just unveiled an announcement.
On March 13, 2026, Progyny, Inc. announced it had issued a Notice of Pendency of Settlement of a shareholder derivative action filed in New York state court, resolving claims that its board approved excessive compensation for non-employee directors since 2020. The settlement, which remains subject to court approval, stems from litigation brought in April 2025 alleging breach of fiduciary duty and unjust enrichment related to director pay.
Under the agreement, Progyny will implement corporate governance reforms within ten business days of the settlement’s effective date, to be maintained for at least four years. These changes include a new director compensation policy that caps annual cash and equity awards, specifies how awards may be structured, limits supplemental grants, and restricts other forms of director compensation, delivering benefits to the company and its shareholders without any direct monetary payout to investors.
The most recent analyst rating on (PGNY) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Progyny stock, see the PGNY Stock Forecast page.
Spark’s Take on PGNY Stock
According to Spark, TipRanks’ AI Analyst, PGNY is a Outperform.
Overall score reflects strong financial quality (robust free cash flow and low leverage) and a constructive earnings update (raised guidance, strong renewals, and buyback), offset by weak technicals (price below major moving averages with negative MACD) and a valuation that is not particularly cheap (P/E ~27 with no dividend yield provided).
To see Spark’s full report on PGNY stock, click here.
More about Progyny
Progyny, Inc. is a New York-based Delaware corporation that provides fertility, family building, and women’s reproductive health benefits to employers and their employees. Its offerings span preconception care, fertility treatments, pregnancy support, postpartum care, and menopause support, positioning the company in the specialized employer-sponsored health benefits market for reproductive care.
Average Trading Volume: 1,583,418
Technical Sentiment Signal: Sell
Current Market Cap: $1.43B
Find detailed analytics on PGNY stock on TipRanks’ Stock Analysis page.